A Study of ART0380 for the Treatment of Advanced or Metastatic Solid Tumors
A phase 1/2 trial of Gemcitabine, FOLFIRI, Irinotecan in metastatic cancer and ovarian cancer, run by Artios Pharma Ltd, now recruiting.
Overview
A Study of ART0380 for the Treatment of Advanced or Metastatic Solid Tumors is a phase 1/2 interventional study registered as NCT04657068 by Artios Pharma Ltd, with 542 participants planned, started 2021-01-27 and due to reach its primary completion in 2028-01. Interventions recorded: ART0380, Gemcitabine, Irinotecan. Conditions listed: Advanced Cancer, Metastatic Cancer, Ovarian Cancer, Primary Peritoneal Cancer. No results are recorded here; the registry entry is the source.
Similar pages
not linked directly; found by shared links- TrialAZD0901 in Participants With Advanced Solid Tumours Expressing Claudin18.2
Shares Irinotecan (and liposomal irinotecan), FOLFIRI (5-FU, leucovorin, irinotecan), Gemcitabine, Pancreatic ductal adenocarcinoma.
- TrialA Study of DM002 in Patients With Advanced Solid Tumors
Shares Endometrial cancer, Ovarian cancer, Pancreatic ductal adenocarcinoma, Colorectal cancer.
- TrialThe Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)
Shares Endometrial cancer, Ovarian cancer, Metastatic cancer (cancer that has spread), Colorectal cancer.
- TrialA Study of a Selective T Cell Receptor (TCR) Targeting, Bifunctional Antibody-fusion Molecule STAR0602 in Participants With Advanced Solid Tumors
Shares Irinotecan (and liposomal irinotecan), FOLFIRI (5-FU, leucovorin, irinotecan), Colorectal cancer.
- TrialA Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Antitumor Activity of INV-8989 in Patients With Advanced Solid Tumors Harboring KRAS G12D Mutations
Shares Endometrial cancer, Ovarian cancer, Pancreatic ductal adenocarcinoma, Colorectal cancer.
- TrialA Study of PARG Inhibitor ETX-19477 in Patients With Advanced Solid Malignancies
Shares Endometrial cancer, Ovarian cancer, Colorectal cancer.
- TrialStudy of Combined SGT-53 Plus Gemcitabine/Nab-Paclitaxel for Metastatic Pancreatic Cancer
- TrialIntra-arterial Gemcitabine vs. IV Gemcitabine and Nab-Paclitaxel Following Radiotherapy for LAPC